Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1

For the PEARL consortium

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


The clinical heterogeneity of prostate cancer (PCa) makes it difficult to identify those patients that could benefit from more aggressive treatments. As a contribution to a better understanding of the genomic changes in the primary tumor that are associated with the development of high-risk disease, we performed exome sequencing and copy number determination of a clinically homogeneous cohort of 47 high-risk PCas. We confirmed recurrent mutations in SPOP, PTEN and TP53 among the 850 point mutations we detected. In seven cases, we discovered genomic aberrations in the TET1 (Ten-Eleven Translocation 1) gene which encodes a DNA hydroxymethylase than can modify methylated cytosines in genomic DNA and thus is linked with gene expression changes. TET1 protein levels were reduced in tumor versus non-tumor prostate tissue in 39 of 40 cases. The clinical relevance of changes in TET1 levels was demonstrated in an independent PCa cohort, in which low TET1 mRNA levels were significantly associated with worse metastases-free survival. We also demonstrate a strong reduction in hydroxymethylated DNA in tumor tissue in 27 of 41 cases. Furthermore, we report the first exploratory (h)MeDIP-Seq analyses of eight high-risk PCa samples. This reveals a large heterogeneity in hydroxymethylation changes in tumor versus non-tumor genomes which can be linked with cell polarity.

Original languageEnglish (US)
Pages (from-to)24326-24338
Number of pages13
Issue number17
StatePublished - Apr 26 2016


  • DNA
  • Epigenetics
  • Genomics
  • High-risk prostate cancer
  • Hydroxymethylation
  • TET1

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1'. Together they form a unique fingerprint.

Cite this